Table 2 Ruxolitinib dose modifications recommended for MF patients with a starting platelet count of at least 50 × 10 9 /L but less than 100 × 10 9 /L*
Current platelet count | Dosing recommendation |
|---|---|
<25 × 109/L | Interrupt treatment |
25 to <35 × 109/L with <20% decrease during the prior 4 weeks | Decrease dose by 5 mg QD or maintain the current dose if it is 5 mg QD |
25 to <35 × 109/L with ≥20% decrease during prior 4 weeks | Decrease dose by 5 mg BID or use 5 mg QD if the current dose is 5 mg BID or QD |
≥40 × 109/L with ≤20% decrease during prior 4 weeks, ANC >1 × 109/L, and no dose reductions or treatment interruptions for AE or hematologic toxicity during the prior 4 weeks | Increase dose by increments of 5 mg QD to a maximum of 10 mg BID if response is insufficient |